CD86 and neoplasm: After JHU083 treatment, the in vivo TAMs were more phagocytic of tumor cells (Fig. 3B), and, importantly, this increased phagocytosis was observed in both CD206+ M2 TAMs and CD86+MHCII+ M1 TAMs (Fig. 3C; Supplementary Fig. S3B).